Opioid withdrawal resident survival guide: Difference between revisions

Jump to navigation Jump to search
Line 48: Line 48:
{{familytree | | | C01 | | | | | | | | | |C01=❑ Admit the patient }}
{{familytree | | | C01 | | | | | | | | | |C01=❑ Admit the patient }}
{{familytree | | | |!| | | | | | | | | | | }}
{{familytree | | | |!| | | | | | | | | | | }}
{{familytree | | | D01 | | | | | | | | | |D01=<div style="float: left; text-align: left">'''Start opioid agonists:'''<ref name="Huitink-2003">{{Cite journal  | last1 = Huitink | first1 = J. | last2 = Buitelaar | first2 = D. | title = Management of drug and alcohol withdrawal. | journal = N Engl J Med | volume = 349 | issue = 4 | pages = 405-7; author reply 405-7 | month = Jul | year = 2003 | doi =  | PMID = 12879900 }}</ref><br> ❑ Methadone (pure agonist) 20-35 mg daily<br>
{{familytree | | | D01 | | | | | | | | | |D01=<div style="float: left; text-align: left">❑  '''Start opioid agonists:'''<ref name="Huitink-2003">{{Cite journal  | last1 = Huitink | first1 = J. | last2 = Buitelaar | first2 = D. | title = Management of drug and alcohol withdrawal. | journal = N Engl J Med | volume = 349 | issue = 4 | pages = 405-7; author reply 405-7 | month = Jul | year = 2003 | doi =  | PMID = 12879900 }}</ref><br>
'''or'''<br>
:❑ Methadone (pure agonist) 20-35 mg daily, or<br>
❑ Buprenorphine (partial agonist) 4-16 mg sublingual daily  <br> ❑ Taper by 3% daily over next several days
:❑ Buprenorphine (partial agonist) 4-16 mg sublingual daily  <br>
❑ Taper by 3% daily over next several days
<ref name="Senay-1977">{{Cite journal  | last1 = Senay | first1 = EC. | last2 = Dorus | first2 = W. | last3 = Goldberg | first3 = F. | last4 = Thornton | first4 = W. | title = Withdrawal from methadone maintenance. Rate of withdrawal and expectation. | journal = Arch Gen Psychiatry | volume = 34 | issue = 3 | pages = 361-7 | month = Mar | year = 1977 | doi =  | PMID = 843188 }}</ref>
<ref name="Senay-1977">{{Cite journal  | last1 = Senay | first1 = EC. | last2 = Dorus | first2 = W. | last3 = Goldberg | first3 = F. | last4 = Thornton | first4 = W. | title = Withdrawal from methadone maintenance. Rate of withdrawal and expectation. | journal = Arch Gen Psychiatry | volume = 34 | issue = 3 | pages = 361-7 | month = Mar | year = 1977 | doi =  | PMID = 843188 }}</ref>
----
----
'''Add nonopioid drugs:'''<br>❑ [[Clonidine]] 0.2 mg every 4 hours, tapered after day 3 <ref name="O'Connor-1995">{{Cite journal  | last1 = O'Connor | first1 = PG. | last2 = Waugh | first2 = ME. | last3 = Carroll | first3 = KM. | last4 = Rounsaville | first4 = BJ. | last5 = Diagkogiannis | first5 = IA. | last6 = Schottenfeld | first6 = RS. | title = Primary care-based ambulatory opioid detoxification: the results of a clinical trial. | journal = J Gen Intern Med | volume = 10 | issue = 5 | pages = 255-60 | month = May | year = 1995 | doi =  | PMID = 7616334 }}</ref><br>
'''Add nonopioid drugs:'''<br>
'''or''' <br>
:❑ [[Clonidine]] 0.2 mg every 4 hours, tapered after day 3,<ref name="O'Connor-1995">{{Cite journal  | last1 = O'Connor | first1 = PG. | last2 = Waugh | first2 = ME. | last3 = Carroll | first3 = KM. | last4 = Rounsaville | first4 = BJ. | last5 = Diagkogiannis | first5 = IA. | last6 = Schottenfeld | first6 = RS. | title = Primary care-based ambulatory opioid detoxification: the results of a clinical trial. | journal = J Gen Intern Med | volume = 10 | issue = 5 | pages = 255-60 | month = May | year = 1995 | doi =  | PMID = 7616334 }}</ref> or<br>
❑ [[Lofexidine]] 0.2 mg BD daily, titrated to 1.2 mg BD daily <ref name="Strang-1999">{{Cite journal  | last1 = Strang | first1 = J. | last2 = Bearn | first2 = J. | last3 = Gossop | first3 = M. | title = Lofexidine for opiate detoxification: review of recent randomised and open controlled trials. | journal = Am J Addict | volume = 8 | issue = 4 | pages = 337-48 | month =  | year = 1999 | doi =  | PMID = 10598217 }}</ref><br>
:❑ [[Lofexidine]] 0.2 mg BD daily, titrated to 1.2 mg BD daily <ref name="Strang-1999">{{Cite journal  | last1 = Strang | first1 = J. | last2 = Bearn | first2 = J. | last3 = Gossop | first3 = M. | title = Lofexidine for opiate detoxification: review of recent randomised and open controlled trials. | journal = Am J Addict | volume = 8 | issue = 4 | pages = 337-48 | month =  | year = 1999 | doi =  | PMID = 10598217 }}</ref><br>
Chlordiazepoxide as needed
Administer chlordiazepoxide as needed
<br> ❑ Treatment duration 10 days for heroin; 14 days for methadone
----
----
❑ Provide general symptomatic management
❑ Provide general symptomatic management

Revision as of 16:24, 31 January 2014

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Vidit Bhargava, M.B.B.S [2]; Vendhan Ramanujam M.B.B.S [3]

Definition

Opioid withdrawal refers to the arrays of signs and symptoms following the abrupt cessation of opioids among chronic users.

Shown below is a table indicative of time to withdrawal symptoms for different opioids:[1][2]


Opioid Peak withdrawal symptoms Duration of symptoms
Heroin 36-72 hours 7-10 days
Methadone 72-96 hours 14 days or more
Buprenorphine 36-72 hours Intermediate between 7-14 days

Causes

Life Threatening Causes

Life-threatening causes include conditions which may result in death or permanent disability within 24 hours if left untreated. Opioid withdrawal is a life-threatening condition and must be treated as such irrespective of the causes.

Common Causes

Management

Shown below is an algorithm depicting the management of opioid withdrawal based on hospital concepts.[3]

 
 
Characterize the symptoms:
❑ Flu like illness
❑ Lacrimation
❑ Rhinorrhea
❑ Sneezing
❑ Yawning
Anorexia
Nausea
❑ Vomiting
❑ Abdominal cramps
Diarrhea
Myalgia
Arthralgia
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Examine the patient:
❑ Increased or unchanged blood pressure
❑ Increased or unchanged heart rate
❑ Increased or unchanged respiratory rate
Mydriasis
❑ Piloerection
Tremor
❑ Increased bowel sounds
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Consider alternative diagnosis:
❑ Alcohol withdrawal
Sedative hypnotic withdrawal
Cholinergic poisoning
Sympathomimetic intoxication
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
❑ Admit the patient
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Start opioid agonists:[3]
❑ Methadone (pure agonist) 20-35 mg daily, or
❑ Buprenorphine (partial agonist) 4-16 mg sublingual daily

❑ Taper by 3% daily over next several days [4]


Add nonopioid drugs:

Clonidine 0.2 mg every 4 hours, tapered after day 3,[5] or
Lofexidine 0.2 mg BD daily, titrated to 1.2 mg BD daily [6]

❑ Administer chlordiazepoxide as needed


❑ Provide general symptomatic management


❑ Consult psychiatry

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Detoxification[3]
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Rapid detoxification:[7]
For a patient receiving about 8 mg of buprenorphine or 35 mg of methadone
❑ Detoxify while awake or under mild sedation
❑ Add naltrexone
❑ Day 1: 25 mg
❑ Days 2 to 15: 50 mg

❑ Add clonidine 0.1-0.2 mg four times daily, tapered on days 2 and 3

❑ Administer antiemetic agents as needed
❑ Administer analgesics as needed
 
Ultra rapid detoxification:[8][9]
❑ Detoxify under heavy sedation or general anesthesia
❑ Induce acute withdrawal with naloxone
❑ Consider intubation and mechanical ventilation if necessary
❑ Administer antiemetic agents as needed
❑ Administer analgesics as needed
 
 
 
 
 

BID: Twice daily

Do's

  • Restrict methadone and other opioid agonists to inpatient settings or licensed programs.
  • Administer chlordiazepoxide, a longer-acting benzodiazepine to augment clonidine in patients with insomnia or muscle cramps.[5]
  • Detoxification should be undertaken only under clinicians with special training, equipment, or both.
  • Start buprenorphine at least two days before starting naltrexone during detoxification.

Dont's

  • Do not abruptly stop drugs that are being used to treat withdrawal.

References

  1. Jasinski, DR.; Pevnick, JS.; Griffith, JD. (1978). "Human pharmacology and abuse potential of the analgesic buprenorphine: a potential agent for treating narcotic addiction". Arch Gen Psychiatry. 35 (4): 501–16. PMID 215096. Unknown parameter |month= ignored (help)
  2. Opiods: detoxification. In: Galanter M, Kleber HD, eds. The American Psychiatric Press textbook of substance abuse treatment. 2nd ed. Washington, D.C.: American Psychiatric Press, 1999:251-69.>
  3. 3.0 3.1 3.2 Huitink, J.; Buitelaar, D. (2003). "Management of drug and alcohol withdrawal". N Engl J Med. 349 (4): 405–7, author reply 405-7. PMID 12879900. Unknown parameter |month= ignored (help)
  4. Senay, EC.; Dorus, W.; Goldberg, F.; Thornton, W. (1977). "Withdrawal from methadone maintenance. Rate of withdrawal and expectation". Arch Gen Psychiatry. 34 (3): 361–7. PMID 843188. Unknown parameter |month= ignored (help)
  5. 5.0 5.1 O'Connor, PG.; Waugh, ME.; Carroll, KM.; Rounsaville, BJ.; Diagkogiannis, IA.; Schottenfeld, RS. (1995). "Primary care-based ambulatory opioid detoxification: the results of a clinical trial". J Gen Intern Med. 10 (5): 255–60. PMID 7616334. Unknown parameter |month= ignored (help)
  6. Strang, J.; Bearn, J.; Gossop, M. (1999). "Lofexidine for opiate detoxification: review of recent randomised and open controlled trials". Am J Addict. 8 (4): 337–48. PMID 10598217.
  7. O'Connor, PG.; Carroll, KM.; Shi, JM.; Schottenfeld, RS.; Kosten, TR.; Rounsaville, BJ. (1997). "Three methods of opioid detoxification in a primary care setting. A randomized trial". Ann Intern Med. 127 (7): 526–30. PMID 9313020. Unknown parameter |month= ignored (help)
  8. Presslich, O.; Loimer, N.; Lenz, K.; Schmid, R. (1989). "Opiate detoxification under general anesthesia by large doses of naloxone". J Toxicol Clin Toxicol. 27 (4–5): 263–70. PMID 2600989.
  9. Loimer, N.; Lenz, K.; Schmid, R.; Presslich, O. (1991). "Technique for greatly shortening the transition from methadone to naltrexone maintenance of patients addicted to opiates". Am J Psychiatry. 148 (7): 933–5. PMID 2053636. Unknown parameter |month= ignored (help)


Template:WikiDoc Sources